Company Overview - Taiankang Pharmaceutical Co., Ltd. is located in Shantou, Guangdong Province, established on January 22, 1999, and listed on March 29, 2022 [1] - The company's main business includes the agency operation, research and development, production, and sales of pharmaceutical products, medical devices, and health materials, as well as providing pharmaceutical technology services and technology transfer [1] - The revenue composition is as follows: pharmaceutical agency 65.16%, pharmaceutical manufacturing 31.70%, pharmaceutical technology services and technology transfer 2.97%, and others 0.17% [1] Stock Performance - As of September 16, Taiankang's stock price increased by 2.05%, reaching 38.37 CNY per share, with a trading volume of 215 million CNY and a turnover rate of 1.86%, resulting in a total market capitalization of 16.326 billion CNY [1] - Year-to-date, the stock price has risen by 159.41%, with a 2.81% increase over the last five trading days, 7.78% over the last 20 days, and 9.79% over the last 60 days [1] Financial Performance - As of June 30, Taiankang reported a decrease in revenue to 347 million CNY for the first half of 2025, a year-on-year decline of 12.23%, and a net profit attributable to shareholders of 37.08 million CNY, down 56.75% year-on-year [2] - The number of shareholders decreased by 33.05% to 10,900, while the average circulating shares per person increased by 49.36% to 27,747 shares [2] Dividend Information - Since its A-share listing, Taiankang has distributed a total of 460 million CNY in dividends, with 377 million CNY distributed over the past three years [3]

Core Viewpoint - The stock of Ailis has experienced fluctuations, with a notable decline of 2.02% on September 16, 2023, despite a year-to-date increase of 86.01% [1] Financial Performance - For the first half of 2025, Ailis reported a revenue of 2.374 billion yuan, representing a year-on-year growth of 50.57% [2] - The net profit attributable to shareholders for the same period was 1.051 billion yuan, showing a year-on-year increase of 60.22% [2] Shareholder Information - As of June 30, 2025, Ailis had 13,000 shareholders, an increase of 3.61% from the previous period [2] - The average number of circulating shares per shareholder was 34,578, a decrease of 3.48% [2] Dividend Distribution - Ailis has distributed a total of 653 million yuan in dividends since its A-share listing [3] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included notable entities such as Huaxia SSE Sci-Tech 50 ETF, which increased its holdings by 1.3199 million shares to 12.4209 million shares [3] - Hong Kong Central Clearing Limited reduced its holdings by 246,090 shares to 10.3778 million shares [3] - New institutional shareholder, China Europe Medical Health Mixed A, holds 9.1525 million shares [3]

Core Viewpoint - The stock of Yipinhong has experienced significant fluctuations, with a year-to-date increase of 257.15%, but a recent decline in the last five and twenty trading days, indicating potential volatility in the market [1]. Financial Performance - For the first half of 2025, Yipinhong reported a revenue of 584 million yuan, a year-on-year decrease of 36.02%, and a net profit attributable to shareholders of -73.54 million yuan, a decline of 258.30% [2]. - The company has distributed a total of 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 16, Yipinhong's stock price was 60.93 yuan per share, with a market capitalization of 27.522 billion yuan. The stock saw a trading volume of 124 million yuan and a turnover rate of 0.48% [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1]. Shareholder Information - As of August 31, the number of shareholders for Yipinhong was 21,400, an increase of 0.49% from the previous period, with an average of 19,553 circulating shares per shareholder, a decrease of 0.49% [2]. - Among the top ten circulating shareholders, Yifangda Healthcare Industry Mixed A has entered the list as the eighth largest shareholder, holding 4.3661 million shares [3].

Core Viewpoint - The stock of Haishike experienced a decline of 2.03% on September 15, 2023, with a current price of 56.90 CNY per share and a total market capitalization of 63.723 billion CNY, despite a year-to-date increase of 72.53% [1] Financial Performance - For the first half of 2025, Haishike reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2] - Cumulative cash dividends since the A-share listing amount to 3.673 billion CNY, with 687 million CNY distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 25.93% to 11,400, with an average of 42,147 circulating shares per shareholder, down by 28.64% [2] - The top ten circulating shareholders include several funds, with notable increases in holdings by China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A [3]

Group 1 - Dashi Intelligent signed a contract worth 23.86 million yuan for the Xiaomi Wuhan Phase II smart project, providing a comprehensive smart space solution [1] - ST Tian Sheng's subsidiary passed the consistency evaluation for sodium bicarbonate injection, used for treating metabolic acidosis and certain drug poisonings [1] - Yongyue Technology's actual controller Chen Xiang was released on bail due to allegations of information disclosure violations, while the company's operations remain normal [2] Group 2 - Jushen Co. experienced a stock price fluctuation with a cumulative increase of over 20% over three trading days, while also planning to reduce repurchased shares [2][3] - Shanghai Airport reported a 6.9% year-on-year increase in passenger throughput at Pudong International Airport, totaling 7.9471 million passengers in August [3][4] - Jianlong Micro-Nano announced plans for shareholders to reduce up to 3% of company shares due to fund expiration and exit arrangements [5][6] Group 3 - Yunyong Technology's shareholders plan to reduce up to 2.99% of company shares due to personal funding needs [6] - Zitian Tui's stock entered a delisting arrangement period, expected to last 15 trading days [7] - Pruis's shareholders plan to reduce up to 3% of company shares for personal funding needs [9] Group 4 - Dayilong's shareholders plan to reduce up to 3% of company shares for personal financial arrangements [10] - Yihua New Materials' shareholders plan to reduce up to 1% of company shares for personal funding needs [12] - Huibo Yuntong's controlling shareholder's affiliates plan to acquire a controlling stake in Baode Computer [13] Group 5 - Wanda Information's shareholders plan to reduce up to 3% of company shares for operational needs [14] - Jiafa Education's shareholders plan to reduce up to 3% of company shares for personal funding needs [15] - Guangkang Biochemical's shareholders plan to reduce up to 1.8% of company shares for personal funding needs [16] Group 6 - Yingxin Development's shareholders plan to reduce up to 0.67% of company shares due to bankruptcy asset disposal [18] - Weiye Co.'s shareholders plan to reduce a total of up to 2% of company shares [19] - Kelin Electric plans to raise up to 1.5 billion yuan through a private placement to supplement working capital [20]

Company Overview - Fosun Pharma's stock price increased by 2.03% on September 15, reaching 32.16 CNY per share, with a trading volume of 8.01 billion CNY and a turnover rate of 1.19%, resulting in a total market capitalization of 858.81 billion CNY [1] - The company was established on May 31, 1995, and listed on August 7, 1998, with its main business focusing on drug manufacturing and research, covering medical devices, medical services, and pharmaceutical distribution and retail [1] Financial Performance - For the first half of 2025, Fosun Pharma reported a revenue of 19.514 billion CNY, a year-on-year decrease of 4.63%, while the net profit attributable to shareholders increased by 38.96% to 1.702 billion CNY [2] - The company has distributed a total of 12.593 billion CNY in dividends since its A-share listing, with 2.691 billion CNY distributed over the past three years [2] Stockholder Information - As of June 30, 2025, the number of shareholders decreased by 4.37% to 230,000, with an average of 0 circulating shares per shareholder [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 75.8807 million shares, an increase of 11.1938 million shares from the previous period [3]

Core Insights - The stock price of Haisun Pharmaceutical experienced a decline of 2.01% on September 15, trading at 66.29 CNY per share with a total market capitalization of 7.955 billion CNY [1] - The company has seen a significant stock price increase of 230.46% year-to-date, but has recently faced a decline of 14.88% over the past five trading days [1] Company Overview - Haisun Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, is located in Nanjing Economic and Technological Development Zone, Jiangsu Province [2] - The company's main business includes the research, production, and sales of chemical preparations, raw materials, and intermediates, with a revenue composition heavily weighted towards cardiovascular drugs at 87.12% [2] Financial Performance - For the first half of 2025, Haisun Pharmaceutical reported a revenue of 309 million CNY, reflecting a year-on-year growth of 30.46%, and a net profit attributable to shareholders of 29.16 million CNY, up 17.87% year-on-year [2] - The company has distributed a total of 161 million CNY in dividends since its A-share listing, with 18 million CNY distributed over the past three years [3] Shareholder Information - As of September 10, the number of shareholders for Haisun Pharmaceutical increased to 21,800, a rise of 10.57%, while the average circulating shares per person decreased by 9.56% to 3,773 shares [2]

Core Viewpoint - As of September 15, 2023, Aosaikang's stock price has shown significant volatility, with a year-to-date increase of 76.65% but a recent decline in the last 20 days by 15.41% [1] Financial Performance - For the first half of 2025, Aosaikang reported a revenue of 1.007 billion yuan, representing a year-on-year growth of 9.20%, and a net profit attributable to shareholders of 160 million yuan, which is a substantial increase of 111.64% [2] - Cumulative cash dividends since Aosaikang's A-share listing amount to 721 million yuan, with 111 million yuan distributed over the past three years [3] Shareholder Structure - As of August 20, 2023, Aosaikang had 18,300 shareholders, a decrease of 1.26% from the previous period, with an average of 50,724 circulating shares per shareholder, an increase of 1.28% [2] - Notable changes in institutional holdings include new entries such as Yongying Pharmaceutical Innovation Mixed Fund and Hong Kong Central Clearing Limited, while some funds like China Europe Medical Health Mixed Fund have exited the top ten shareholders list [3] Market Activity - On September 15, 2023, Aosaikang's stock experienced a decline of 2.03%, trading at 22.24 yuan per share, with a total market capitalization of 20.642 billion yuan [1] - The stock has seen a net inflow of 3.5584 million yuan from major funds, with significant buying activity accounting for 11.74% of total transactions [1]

Core Viewpoint - BeiGene's stock has shown significant growth this year, with a year-to-date increase of 99.95%, indicating strong market performance and investor interest [1][2]. Group 1: Stock Performance - As of September 15, BeiGene's stock price reached 321.96 CNY per share, with a trading volume of 8.29 billion CNY and a turnover rate of 2.27%, resulting in a total market capitalization of 496.04 billion CNY [1]. - The stock has experienced a 1.25% increase over the last five trading days, a 32.49% increase over the last 20 days, and a 28.58% increase over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a stock trading list) once this year, with the most recent appearance on September 2 [1]. Group 2: Financial Performance - For the first half of 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03%, and a net profit attributable to shareholders of 450 million CNY, which is a 115.63% increase compared to the previous period [2]. - The number of shareholders decreased by 3.90% to 23,300 as of June 30, 2025, while the average number of circulating shares per person increased by 4.11% to 4,976 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, the fourth largest shareholder is 中欧医疗健康混合A (China Europe Medical Health Mixed A) with 4.8254 million shares, an increase of 1.2436 million shares from the previous period [2]. - 万家优选 (Wanjia Youxuan) is the sixth largest shareholder with 3 million shares, a decrease of 500,000 shares [2]. - 新进股东 (new shareholder) 南方中证500ETF (Southern CSI 500 ETF) holds 1.7259 million shares [2].

资料显示，苏州泽璟生物制药股份有限公司位于江苏省昆山市玉山镇晨丰路262号，成立日期2009年3月 18日，上市日期2020年1月23日，公司主营业务涉及化学新药及生物新药的研发、生产及销售。主营业 务收入构成为：药品99.97%，医药中间体及原辅料0.02%，资产租赁0.00%。 9月15日，泽璟制药盘中上涨2.12%，截至09:44，报114.89元/股，成交5408.06万元，换手率0.18%，总 市值304.12亿元。 资金流向方面，主力资金净流入208.34万元，特大单买入367.58万元，占比6.80%，卖出0.00元，占比 0.00%；大单买入638.20万元，占比11.80%，卖出797.44万元，占比14.75%。 泽璟制药今年以来股价涨84.38%，近5个交易日跌2.50%，近20日涨3.50%，近60日涨1.08%。 机构持仓方面，截止2025年6月30日，泽璟制药十大流通股东中，中欧医疗健康混合A（003095）位居 第五大流通股东，持股816.63万股，相比上期增加268.75万股。广发医疗保健股票A（004851）位居第 六大流通股东，持股527.45万股，相比上期减少117.14 ...